Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial
Abstract Background Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-ter...
Gespeichert in:
| Veröffentlicht in: | Schizophrenia research 2013-07, Vol.147 (2), p.375-382 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 382 |
|---|---|
| container_issue | 2 |
| container_start_page | 375 |
| container_title | Schizophrenia research |
| container_volume | 147 |
| creator | Crespo-Facorro, Benedicto Ortiz-García de la Foz, Victor Mata, Ignacio Ayesa-Arriola, Rosa Suarez-Pinilla, Paula Valdizan, Elsa M Vázquez-Barquero, José Luis Pérez-Iglesias, Rocío |
| description | Abstract Background Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-term of Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode schizophrenia-spectrum disorders. Method From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. 202 first-episode drug-naïve patients were randomly assigned to Aripiprazole (N = 78), Ziprasidone (N = 62), or Quetiapine (N = 62) and followed-up for 3 months. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat populations was conducted in the analysis for clinical efficacy. Results The overall dropout rate at 3 months was small (13.86%). The treatment discontinuation rate differed significantly between treatment groups (Aripiprazole = 23.1%, Ziprasidone = 37.1% and Quetiapine = 61.3%) (χ2 = 21.334; p < 0.001). Insufficient efficacy in the group of Quetiapine is the main reason for discontinuation rate differences (χ2 = 20.223; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 23.467 p < 0.001). Aripiprazole and Quetiapine were associated with a greater depressive symptoms improvement (p = 0.043). The profile of side-effects varies between treatments. Patients on Quetiapine were less likely to be prescribed hypnotics. Conclusions Patients treated with Quetiapine had a higher risk of treatment discontinuation in the short-term after a first episode due to insufficient efficacy. Establishing differences between SGAs may help clinicians in prescribing decisions for the treatment of individuals presenting with first-episode schizophrenia. |
| doi_str_mv | 10.1016/j.schres.2013.04.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1366579241</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0920996413002144</els_id><sourcerecordid>1366579241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-40f645931e5e19f1c74aff856ffd3fd50c448b1dcb4b7ccb3d44230438e7abc33</originalsourceid><addsrcrecordid>eNqFks-KFDEQxhtR3HH1DURyETxst0kn3T3tYWFY_AcLIurFS0gnFaZmM0mbdK_OPomPa5oZFbx4SgV-VV_xfVUUTxmtGGXty12V9DZCqmrKeEVFRZm4V6xY0_Gybmh_v1jRvqZl37firHiU0o5SyhraPSzOat4Kzuv1qvi5iTjiGNVdcHBBvi5lQhM8EOUN-TjDhGrE_EVPpi2QKYKa9uAnEiyxGNNUwogpGCA-eGUt6AlvgYzpoLchYXpFNoTV5XeAGxLzzLDHOzAXxDr4gYOD0oSUlcMIvnRqAJclULnHxQOrXIInp_e8-PLm9eerd-X1h7fvrzbXpW4Yn0pBbSuanjNogPWW6U7kHdZNa63h1jRUC7EemNGDGDqtB26EqDkVfA2dGjTn58WL49wxhm8zpEnuMWlwTnkIc5KMt23T9bVgGRVHVMeQUgQrx4h7FQ-SUblkInfymIlcMpFUyJxJbnt2UpiHPZg_Tb9DyMDzE6CSVs5mlzSmv1wn2p62beYujxxkP24RYlZD8BoMxuy6NAH_t8m_A7RDj1nzBg6QdmGOPnstmUy1pPLTcj_L-TBOac2E4L8ABQPDog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1366579241</pqid></control><display><type>article</type><title>Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Crespo-Facorro, Benedicto ; Ortiz-García de la Foz, Victor ; Mata, Ignacio ; Ayesa-Arriola, Rosa ; Suarez-Pinilla, Paula ; Valdizan, Elsa M ; Vázquez-Barquero, José Luis ; Pérez-Iglesias, Rocío</creator><creatorcontrib>Crespo-Facorro, Benedicto ; Ortiz-García de la Foz, Victor ; Mata, Ignacio ; Ayesa-Arriola, Rosa ; Suarez-Pinilla, Paula ; Valdizan, Elsa M ; Vázquez-Barquero, José Luis ; Pérez-Iglesias, Rocío</creatorcontrib><description>Abstract Background Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-term of Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode schizophrenia-spectrum disorders. Method From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. 202 first-episode drug-naïve patients were randomly assigned to Aripiprazole (N = 78), Ziprasidone (N = 62), or Quetiapine (N = 62) and followed-up for 3 months. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat populations was conducted in the analysis for clinical efficacy. Results The overall dropout rate at 3 months was small (13.86%). The treatment discontinuation rate differed significantly between treatment groups (Aripiprazole = 23.1%, Ziprasidone = 37.1% and Quetiapine = 61.3%) (χ2 = 21.334; p < 0.001). Insufficient efficacy in the group of Quetiapine is the main reason for discontinuation rate differences (χ2 = 20.223; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 23.467 p < 0.001). Aripiprazole and Quetiapine were associated with a greater depressive symptoms improvement (p = 0.043). The profile of side-effects varies between treatments. Patients on Quetiapine were less likely to be prescribed hypnotics. Conclusions Patients treated with Quetiapine had a higher risk of treatment discontinuation in the short-term after a first episode due to insufficient efficacy. Establishing differences between SGAs may help clinicians in prescribing decisions for the treatment of individuals presenting with first-episode schizophrenia.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2013.04.014</identifier><identifier>PMID: 23643328</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Adverse effects ; Analysis of Variance ; Antipsychotic agents ; Antipsychotic Agents - therapeutic use ; Aripiprazole ; Biological and medical sciences ; Dibenzothiazepines - therapeutic use ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Outcome Assessment (Health Care) ; Pharmacology. Drug treatments ; Piperazines - therapeutic use ; Prospective Studies ; Psychiatric Status Rating Scales ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychotherapeutic processes ; Psychotic Disorders - drug therapy ; Quetiapine Fumarate ; Quinolones - therapeutic use ; Retrospective Studies ; Schizophrenia ; Thiazoles - therapeutic use ; Time Factors ; Young Adult</subject><ispartof>Schizophrenia research, 2013-07, Vol.147 (2), p.375-382</ispartof><rights>Elsevier B.V.</rights><rights>2013 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-40f645931e5e19f1c74aff856ffd3fd50c448b1dcb4b7ccb3d44230438e7abc33</citedby><cites>FETCH-LOGICAL-c513t-40f645931e5e19f1c74aff856ffd3fd50c448b1dcb4b7ccb3d44230438e7abc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.schres.2013.04.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27469066$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23643328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crespo-Facorro, Benedicto</creatorcontrib><creatorcontrib>Ortiz-García de la Foz, Victor</creatorcontrib><creatorcontrib>Mata, Ignacio</creatorcontrib><creatorcontrib>Ayesa-Arriola, Rosa</creatorcontrib><creatorcontrib>Suarez-Pinilla, Paula</creatorcontrib><creatorcontrib>Valdizan, Elsa M</creatorcontrib><creatorcontrib>Vázquez-Barquero, José Luis</creatorcontrib><creatorcontrib>Pérez-Iglesias, Rocío</creatorcontrib><title>Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>Abstract Background Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-term of Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode schizophrenia-spectrum disorders. Method From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. 202 first-episode drug-naïve patients were randomly assigned to Aripiprazole (N = 78), Ziprasidone (N = 62), or Quetiapine (N = 62) and followed-up for 3 months. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat populations was conducted in the analysis for clinical efficacy. Results The overall dropout rate at 3 months was small (13.86%). The treatment discontinuation rate differed significantly between treatment groups (Aripiprazole = 23.1%, Ziprasidone = 37.1% and Quetiapine = 61.3%) (χ2 = 21.334; p < 0.001). Insufficient efficacy in the group of Quetiapine is the main reason for discontinuation rate differences (χ2 = 20.223; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 23.467 p < 0.001). Aripiprazole and Quetiapine were associated with a greater depressive symptoms improvement (p = 0.043). The profile of side-effects varies between treatments. Patients on Quetiapine were less likely to be prescribed hypnotics. Conclusions Patients treated with Quetiapine had a higher risk of treatment discontinuation in the short-term after a first episode due to insufficient efficacy. Establishing differences between SGAs may help clinicians in prescribing decisions for the treatment of individuals presenting with first-episode schizophrenia.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Adverse effects</subject><subject>Analysis of Variance</subject><subject>Antipsychotic agents</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Aripiprazole</subject><subject>Biological and medical sciences</subject><subject>Dibenzothiazepines - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Outcome Assessment (Health Care)</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - therapeutic use</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychotherapeutic processes</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Quetiapine Fumarate</subject><subject>Quinolones - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Schizophrenia</subject><subject>Thiazoles - therapeutic use</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks-KFDEQxhtR3HH1DURyETxst0kn3T3tYWFY_AcLIurFS0gnFaZmM0mbdK_OPomPa5oZFbx4SgV-VV_xfVUUTxmtGGXty12V9DZCqmrKeEVFRZm4V6xY0_Gybmh_v1jRvqZl37firHiU0o5SyhraPSzOat4Kzuv1qvi5iTjiGNVdcHBBvi5lQhM8EOUN-TjDhGrE_EVPpi2QKYKa9uAnEiyxGNNUwogpGCA-eGUt6AlvgYzpoLchYXpFNoTV5XeAGxLzzLDHOzAXxDr4gYOD0oSUlcMIvnRqAJclULnHxQOrXIInp_e8-PLm9eerd-X1h7fvrzbXpW4Yn0pBbSuanjNogPWW6U7kHdZNa63h1jRUC7EemNGDGDqtB26EqDkVfA2dGjTn58WL49wxhm8zpEnuMWlwTnkIc5KMt23T9bVgGRVHVMeQUgQrx4h7FQ-SUblkInfymIlcMpFUyJxJbnt2UpiHPZg_Tb9DyMDzE6CSVs5mlzSmv1wn2p62beYujxxkP24RYlZD8BoMxuy6NAH_t8m_A7RDj1nzBg6QdmGOPnstmUy1pPLTcj_L-TBOac2E4L8ABQPDog</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Crespo-Facorro, Benedicto</creator><creator>Ortiz-García de la Foz, Victor</creator><creator>Mata, Ignacio</creator><creator>Ayesa-Arriola, Rosa</creator><creator>Suarez-Pinilla, Paula</creator><creator>Valdizan, Elsa M</creator><creator>Vázquez-Barquero, José Luis</creator><creator>Pérez-Iglesias, Rocío</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial</title><author>Crespo-Facorro, Benedicto ; Ortiz-García de la Foz, Victor ; Mata, Ignacio ; Ayesa-Arriola, Rosa ; Suarez-Pinilla, Paula ; Valdizan, Elsa M ; Vázquez-Barquero, José Luis ; Pérez-Iglesias, Rocío</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-40f645931e5e19f1c74aff856ffd3fd50c448b1dcb4b7ccb3d44230438e7abc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Adverse effects</topic><topic>Analysis of Variance</topic><topic>Antipsychotic agents</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Aripiprazole</topic><topic>Biological and medical sciences</topic><topic>Dibenzothiazepines - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Outcome Assessment (Health Care)</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - therapeutic use</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychotherapeutic processes</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Quetiapine Fumarate</topic><topic>Quinolones - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Schizophrenia</topic><topic>Thiazoles - therapeutic use</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crespo-Facorro, Benedicto</creatorcontrib><creatorcontrib>Ortiz-García de la Foz, Victor</creatorcontrib><creatorcontrib>Mata, Ignacio</creatorcontrib><creatorcontrib>Ayesa-Arriola, Rosa</creatorcontrib><creatorcontrib>Suarez-Pinilla, Paula</creatorcontrib><creatorcontrib>Valdizan, Elsa M</creatorcontrib><creatorcontrib>Vázquez-Barquero, José Luis</creatorcontrib><creatorcontrib>Pérez-Iglesias, Rocío</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crespo-Facorro, Benedicto</au><au>Ortiz-García de la Foz, Victor</au><au>Mata, Ignacio</au><au>Ayesa-Arriola, Rosa</au><au>Suarez-Pinilla, Paula</au><au>Valdizan, Elsa M</au><au>Vázquez-Barquero, José Luis</au><au>Pérez-Iglesias, Rocío</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>147</volume><issue>2</issue><spage>375</spage><epage>382</epage><pages>375-382</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>Abstract Background Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-term of Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode schizophrenia-spectrum disorders. Method From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. 202 first-episode drug-naïve patients were randomly assigned to Aripiprazole (N = 78), Ziprasidone (N = 62), or Quetiapine (N = 62) and followed-up for 3 months. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat populations was conducted in the analysis for clinical efficacy. Results The overall dropout rate at 3 months was small (13.86%). The treatment discontinuation rate differed significantly between treatment groups (Aripiprazole = 23.1%, Ziprasidone = 37.1% and Quetiapine = 61.3%) (χ2 = 21.334; p < 0.001). Insufficient efficacy in the group of Quetiapine is the main reason for discontinuation rate differences (χ2 = 20.223; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 23.467 p < 0.001). Aripiprazole and Quetiapine were associated with a greater depressive symptoms improvement (p = 0.043). The profile of side-effects varies between treatments. Patients on Quetiapine were less likely to be prescribed hypnotics. Conclusions Patients treated with Quetiapine had a higher risk of treatment discontinuation in the short-term after a first episode due to insufficient efficacy. Establishing differences between SGAs may help clinicians in prescribing decisions for the treatment of individuals presenting with first-episode schizophrenia.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>23643328</pmid><doi>10.1016/j.schres.2013.04.014</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-9964 |
| ispartof | Schizophrenia research, 2013-07, Vol.147 (2), p.375-382 |
| issn | 0920-9964 1573-2509 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1366579241 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Adult and adolescent clinical studies Adverse effects Analysis of Variance Antipsychotic agents Antipsychotic Agents - therapeutic use Aripiprazole Biological and medical sciences Dibenzothiazepines - therapeutic use Dose-Response Relationship, Drug Female Humans Male Medical sciences Neuropharmacology Outcome Assessment (Health Care) Pharmacology. Drug treatments Piperazines - therapeutic use Prospective Studies Psychiatric Status Rating Scales Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Psychotherapeutic processes Psychotic Disorders - drug therapy Quetiapine Fumarate Quinolones - therapeutic use Retrospective Studies Schizophrenia Thiazoles - therapeutic use Time Factors Young Adult |
| title | Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A19%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aripiprazole,%20Ziprasidone%20and%20Quetiapine%20in%20the%20treatment%20of%20first-episode%20nonaffective%20psychosis:%20A%2012-week%20randomized,%20flexible-dose,%20open-label%20trial&rft.jtitle=Schizophrenia%20research&rft.au=Crespo-Facorro,%20Benedicto&rft.date=2013-07-01&rft.volume=147&rft.issue=2&rft.spage=375&rft.epage=382&rft.pages=375-382&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2013.04.014&rft_dat=%3Cproquest_cross%3E1366579241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1366579241&rft_id=info:pmid/23643328&rft_els_id=1_s2_0_S0920996413002144&rfr_iscdi=true |